A non-opioid drug that can help reduce or eliminate the need for opioids after surgery is not used as often as it could be because of Medicare’s method of reimbursement, a drug company official said.
And because commercial payers often set their reimbursement based on Medicare policies, the issue is even more significant, noted Dave Stack, chief executive officer of Pacira Pharmaceuticals. Workers' comp fee schedules in many states are also based on Medicare rates.
Pacira Pharmaceuticals makes a product called Exparel that’s sprayed into a surgical site, such as around t...
Comments